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Introduction {#jdi12851-sec-0005}
============

Obesity is an independent factor associated with development of insulin resistance, and it leads to increases in mortality[1](#jdi12851-bib-0001){ref-type="ref"}. Obesity also causes difficulties in treating type 2 diabetes; in particular, visceral fat accumulation is suspected to be correlated with the deterioration of metabolism, as well as the development and progression of cardiovascular diseases[2](#jdi12851-bib-0002){ref-type="ref"}. In recent times, body composition elements other than fat, or lean mass, in addition to body fat accumulation, have come under question in the management of diabetes from not only the perspective of the correction of hyperglycemia, but also the maintenance of quality of life. Sarcopenia[3](#jdi12851-bib-0003){ref-type="ref"}, [4](#jdi12851-bib-0004){ref-type="ref"}, which manifests primarily as decreased skeletal muscle mass, combines with decreased bone mineral content (BMC) and deteriorated bone quality to cause physical frailty, and, thus, increases the risk of developing complications that lower the quality of life and mortality. In the past, there has been concern surrounding type 2 diabetes therapy causing the aforementioned changes in the body components[5](#jdi12851-bib-0005){ref-type="ref"}, [6](#jdi12851-bib-0006){ref-type="ref"}. Therefore, in the clinical care of type 2 diabetes patients, it is important to reduce body fat, as well as maintain the skeletal muscle mass, BMC and bone quality at appropriate levels.

Sodium--glucose cotransporter 2 inhibitors (SGLT2‐i) have a class effect in the suppression of cardiovascular events[7](#jdi12851-bib-0007){ref-type="ref"}, [8](#jdi12851-bib-0008){ref-type="ref"}, and aid in the reduction of body fat[9](#jdi12851-bib-0009){ref-type="ref"}, [10](#jdi12851-bib-0010){ref-type="ref"}. However, there are unanswered questions pertaining to the body components, such as whether or not glycemic improvement and body fat reduction can be achieved, and if sarcopenia is avoidable in Japanese type 2 diabetes patients, who often have a relatively small amount of body fat.

The Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus (LIGHT) Study reported herein was carried out in Japanese type 2 diabetes patients treated with a SGLT2‐i -- luseogliflozin -- for up to 52 weeks, in a prospective setting, to evaluate the changes in the body components in correlation with the changes in metabolism.

Methods {#jdi12851-sec-0006}
=======

Study participants {#jdi12851-sec-0007}
------------------

The study enrolled Japanese outpatients with type 2 diabetes, who visited the medical institutions participating in this study (Table [S1](#jdi12851-sup-0002){ref-type="supplementary-material"}). The participants had a glycated hemoglobin (HbA1c) level ranging from 7.0 to 10.5%, and body mass index (BMI) ranging from 20.0 to 35.0 kg/m^2^, and were aged between 20 and 65 years (Table [S2](#jdi12851-sup-0003){ref-type="supplementary-material"}).

Study drug administration {#jdi12851-sec-0008}
-------------------------

The patients received 2.5 mg of luseogliflozin once daily, in the morning, with an optional uptitration to 5 mg, once daily, at week 12 and thereafter, in the case of insufficient efficacy. In principle, once the dose was downtitrated (2.5 mg), uptitration was not allowed (Table [S3](#jdi12851-sup-0004){ref-type="supplementary-material"}). Medication compliance was checked by an attending physician through an interview at each visit. Each patient was instructed to continue diet therapy for 52 weeks by the physician at enrollment.

Evaluation variables and evaluation period {#jdi12851-sec-0009}
------------------------------------------

The study\'s evaluation variables and time‐points are summarized in Table [S4](#jdi12851-sup-0005){ref-type="supplementary-material"}. The body components were measured using whole‐body dual‐energy X‐ray absorptiometry (DXA; Hologic/Discovery, Hologic/Delphi; Hologic Inc., Marlborough, MA, USA; or GE/Lunar Prodigy enCORE 2006; GE Healthcare, Madison, WI, USA) The visceral fat area and subcutaneous fat area were determined through computed tomography cross‐sectional images of the abdomen at the umbilicus level. Evaluation of the abdominal computed tomography images was carried out at a designated institution by a single predefined radiologist. Subcutaneous fat area and visceral fat area were analyzed using Slim Vision (CYBERNET SYSTEMS CO., LTD., Tokyo, Japan).

As an indicator for skeletal muscles, the skeletal muscle mass index (SMI) was calculated by the equation[3](#jdi12851-bib-0003){ref-type="ref"}: (appendicular lean mass)/(height)^2^, based on the data obtained through DXA. The laboratory tests were carried out by LSI Medience Corporation (Tokyo, Japan). The level of C‐peptide (C‐peptide immunoreactivity) was measured using chemiluminescent immunoassays (ARCHITECT C‐peptide; Abbott Laboratories, Abbott Park, IL, USA), adiponectin levels were determined by a latex agglutination assay (LSI Medience) and insulin levels (immunoreactive insulin) were determined by an electrochemiluminescence immunoassay (Roche Diagnostics, Tokyo, Japan).

Statistical analysis {#jdi12851-sec-0010}
--------------------

For the analysis of the changes in the individual data, the last observation carried forward imputation method was applied. Statistical analyses were carried out using SAS software (version 9.4; SAS Institute Inc., Cary, NC, USA), changes from the baseline were compared using the Wilcoxon signed‐rank test and the correlation among the changes was evaluated using Spearman\'s rank‐order correlation coefficient, with a two‐sided significance level of 5% (*P* \< 0.05). Primary end‐point data and some other data are presented as the mean and 95% confidence interval; all other data are presented as mean ± standard deviations.

Ethical considerations {#jdi12851-sec-0011}
----------------------

The present study was carried out in compliance with the Declaration of Helsinki, and the ethical guideline for clinical research by the Ministry of Health, Labor and Welfare, in Japan. The study protocol was reviewed and approved by the institutional review boards of The Jikei University School of Medicine (approval number: 26‐278) and Independent Ethics Committee (Kitamachi Clinic, approved on 19 August 2014). Informed consent was obtained from all the patients before their participation in this study. The study was registered beforehand at the University Hospital Medical Information Network Clinical Trials Registry (UMIN000015112).

Results {#jdi12851-sec-0012}
=======

Patient characteristics {#jdi12851-sec-0013}
-----------------------

The study enrolled 43 type 2 diabetes patients who were treated as outpatients, between October 2014 and June 2015, after obtaining consent to participate in the study (Figure [S1](#jdi12851-sup-0001){ref-type="supplementary-material"}). The safety analysis set comprised 39 patients who were initially registered for luseogliflozin treatment, and the efficacy analysis set included 37 patients, after the exclusion of two ineligible patients (1 did not meet the HbA1c criterion, and the other did not meet the BMI criterion). The demographic backgrounds of the patients in the efficacy analysis set are summarized in Table [1](#jdi12851-tbl-0001){ref-type="table"}.

###### 

Demographics (efficacy analysis set)

  ------------------------------------------------------------------ -------------
  Age (years)                                                        53.5 ± 8.04
  Body height (cm)                                                   167 ± 8.54
  Duration of disease (years)                                        5.70 ± 4.74
  Sex                                                                
  Male (*n*)                                                         27
  Female (*n*)                                                       10
  Medications                                                        
  Absent (*n*)                                                       9
  Present (*n*)                                                      28
  No. patients by concomitant medication                             
  Only sulfonylurea                                                  1
  Only biguanide                                                     6
  Only dipeptidyl peptidase‐4 inhibitor                              8
  Sulfonylurea + biguanide                                           3
  Biguanide + dipeptidyl peptidase‐4 inhibitor                       7
  Sulfonylurea + biguanide + dipeptidyl peptidase‐4 inhibitor        2
  Biguanide + other[†](#jdi12851-note-0002){ref-type="fn"}           1
  Diabetic complications                                             
  Absent (*n*)                                                       27
  Present (*n*)                                                      10
  No. patients by diabetic complication                              
  Diabetic nephropathy[‡](#jdi12851-note-0002){ref-type="fn"}        5
  Diabetic neuropathy                                                1
  Diabetic retinopathy[§](#jdi12851-note-0002){ref-type="fn"}        6
  Coexisting diseases                                                
  Absent (*n*)                                                       15
  Present (*n*)                                                      22
  No. patients by coexisting disease (some counted multiple times)   
  Hypertension                                                       16
  Ischemic heart disease                                             1
  Dyslipidemia                                                       17
  Hepatic steatosis                                                  4
  ------------------------------------------------------------------ -------------

Data are shown as mean ± standard deviation. ^†^Biguanide + sodium--glucose cotransporter 2 inhibitor + mitiglinide and voglibose. ^‡^Phase of diabetic nephropathy: four patients in phases 1 or 2, one patient in phase 3, no patients in phases 4 or 5. ^§^Phase of diabetic retinopathy: three patients with simple retinopathy, one patient with pre‐proliferative retinopathy, no patient with proliferative retinopathy and two patients in an unknown phase.
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Changes in glucose metabolism {#jdi12851-sec-0014}
-----------------------------

The changes in the metabolic parameters are presented in Table [2](#jdi12851-tbl-0002){ref-type="table"} and Table [S5](#jdi12851-sup-0006){ref-type="supplementary-material"}. From week 4 through week 52, a significant decrease was observed both in the fasting plasma glucose and HbA1c levels, relative to those at the baseline. A biphasic pattern, with a rapid decrease in both the parameters, was noticed until week 8, followed by a stable phase, without a significant difference in the fasting plasma glucose and HbA1c levels between week 24 and week 52.

###### 

Changes in the clinical parameters

                                        *n*                                               Baseline         Change from the baseline                                                                                                                                                
  ------------------------------------- ------------------------------------------------- ---------------- -------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ----------------------------------------------
  Glycemic control                      FPG (mmol/L)                                      37               9.47 ± 2.47                −1.54 ± 1.58                                   [\*\*\*](#jdi12851-note-0003){ref-type="fn"}   −1.86 ± 1.70                                   [\*\*\*](#jdi12851-note-0003){ref-type="fn"}
  HbA1c (%)                             37                                                7.74 ± 0.731     −0.514 ± 0.658             [\*\*\*](#jdi12851-note-0003){ref-type="fn"}   −0.549 ± 0.570                                 [\*\*\*](#jdi12851-note-0003){ref-type="fn"}   
  F‐IRI (pmol/L)                        37                                                117 ± 110        −35.8 ± 86.0               [\*\*](#jdi12851-note-0003){ref-type="fn"}     −36.1 ± 71.7                                   [\*\*\*](#jdi12851-note-0003){ref-type="fn"}   
  F‐CPR (nmol/L)                        37                                                0.777 ± 0.492    −0.124 ± 0.361             [\*](#jdi12851-note-0003){ref-type="fn"}       −0.159 ± 0.346                                 [\*\*](#jdi12851-note-0003){ref-type="fn"}     
  Serum lipids                          HDL‐C (mmol/L)                                    37               1.37 ± 0.381               0.0657 ± 0.272                                                                                0.0839 ± 0.254                                 [\*\*](#jdi12851-note-0003){ref-type="fn"}
  TG (mmol/L)                           37                                                2.25 ± 2.25      −0.314 ± 2.37              [\*](#jdi12851-note-0003){ref-type="fn"}       −0.597 ± 2.01                                  [\*\*\*](#jdi12851-note-0003){ref-type="fn"}   
  LDL‐C (mmol/L)                        37                                                3.19 ± 0.768     0.121 ± 0.649                                                             0.161 ± 0.670                                                                                 
  FFA (μmol/L)                          37                                                602 ± 194        73.8 ± 268                                                                64.3 ± 314                                                                                    
  Blood ketones                         Acetoacetate (μmol/L)                             37               36.5 ± 30.7                45.1 ± 112                                     [\*\*\*](#jdi12851-note-0003){ref-type="fn"}   50.2 ± 104                                     [\*\*\*](#jdi12851-note-0003){ref-type="fn"}
  β‐hydroxybutyrate (μmol/L)            37                                                74.7 ± 78.9      124 ± 373                  [\*\*](#jdi12851-note-0003){ref-type="fn"}     137 ± 338                                      [\*\*\*](#jdi12851-note-0003){ref-type="fn"}   
  pressure/pulse rate                   SBP (mmHg)                                        37               134 ± 13.7                 −2.19 ± 11.3                                                                                  −2.16 ± 13.2                                   
  DBP (mmHg)                            37                                                82.1 ± 10.9      −2.59 ± 10.0                                                              −3.49 ± 9.70                                   [\*](#jdi12851-note-0003){ref-type="fn"}       
  Pulse (beat/min)                      37                                                76.5 ± 11.2      0.486 ± 11.0                                                              0.595 ± 8.62                                                                                  
  Hematology                            RBC (×10^12^/L)                                   37               4.92 ± 0.400               0.200 ± 0.215                                  [\*\*\*](#jdi12851-note-0003){ref-type="fn"}   0.265 ± 0.259                                  [\*\*\*](#jdi12851-note-0003){ref-type="fn"}
  Hemoglobin (g/L)                      37                                                148 ± 13.9       4.11 ± 7.91                [\*\*\*](#jdi12851-note-0003){ref-type="fn"}   6.32 ± 7.19                                    [\*\*\*](#jdi12851-note-0003){ref-type="fn"}   
  Hematocrit (L/L)                      37                                                0.441 ± 0.0396   0.0189 ± 0.0234            [\*\*\*](#jdi12851-note-0003){ref-type="fn"}   0.0235 ± 0.0227                                [\*\*\*](#jdi12851-note-0003){ref-type="fn"}   
  Biochemistry                          BUN (mmol/L)                                      37               4.52 ± 1.20                0.540 ± 0.936                                  [\*\*](#jdi12851-note-0003){ref-type="fn"}     0.521 ± 0.935                                  [\*\*](#jdi12851-note-0003){ref-type="fn"}
  Creatinine (μmol/L)                   37                                                64.0 ± 17.0      0.0478 ± 5.77                                                             −0.239 ± 5.64                                                                                 
  eGFR (mL/min/1.73 m^2^)               37                                                86.9 ± 21.2      −0.462 ± 9.10                                                             −0.481 ± 8.92                                                                                 
  AST (U/L)                             37                                                28.6 ± 11.6      −4.14 ± 7.88               [\*\*\*](#jdi12851-note-0003){ref-type="fn"}   −3.73 ± 8.61                                   [\*\*](#jdi12851-note-0003){ref-type="fn"}     
  ALT (U/L)                             37                                                36.6 ± 18.8      −9.14 ± 13.3               [\*\*\*](#jdi12851-note-0004){ref-type="fn"}   −7.65 ± 15.8                                   [\*\*\*](#jdi12851-note-0003){ref-type="fn"}   
  Adiponectin (mg/L)                    37                                                5.74 ± 1.97      0.446 ± 1.34               [\*\*](#jdi12851-note-0003){ref-type="fn"}     0.151 ± 1.24                                                                                  
  Urinalysis                            Urine albumin corrected by creatinine (mg/g Cr)   37               85.8 ± 193                 −25.4 ± 111                                    [\*](#jdi12851-note-0003){ref-type="fn"}       −13.0 ± 67.9                                   
  Albumin excretion (g/24 h)            20[†](#jdi12851-note-0003){ref-type="fn"}         0.106 ± 0.283    −0.0396 ± 0.105            [\*\*](#jdi12851-note-0003){ref-type="fn"}     0.0122 ± 0.116                                                                                
  Urine output (L/24 h)                 20[†](#jdi12851-note-0003){ref-type="fn"}         1.71 ± 1.04      0.430 ± 0.949              [\*](#jdi12851-note-0003){ref-type="fn"}       0.751 ± 1.68                                   [\*](#jdi12851-note-0003){ref-type="fn"}       
  Urine glucose excretion (mmol/24 h)   20[†](#jdi12851-note-0003){ref-type="fn"}         120 ± 161        402 ± 258                  [\*\*\*](#jdi12851-note-0003){ref-type="fn"}   426 ± 273                                      [\*\*\*](#jdi12851-note-0003){ref-type="fn"}   

^†^Baseline *n* = 22. For each clinical parameter, the baseline value and the mean changes from the baseline are presented with standard deviations. The change at each time‐point was compared with the baseline value using the Wilcoxon signed‐rank test and a significant difference is marked with \*\*\**P* \< 0.001, \*\**P* \< 0.01 or \**P* \< 0.05. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; DBP, diastolic blood pressure; F‐CPR: fasting plasma C‐peptide immunoreactivity; eGFR, estimated glomerular filtration rate; FFA, free fatty acid; F‐IRI: fasting plasma insulin; FPG: fasting plasma glucose; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; RBC, red blood cells; SBP, systolic blood pressure; TG, triglyceride; Urine albumin, result obtained with morning urine and corrected by creatinine; Urine output, 24‐h pooled urine (1/50 proportional sampling).
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Changes in body composition over time {#jdi12851-sec-0015}
-------------------------------------

The changes in each body component, over time, are shown in Figure [1](#jdi12851-fig-0001){ref-type="fig"}, Figure [2](#jdi12851-fig-0002){ref-type="fig"} and Table [3](#jdi12851-tbl-0003){ref-type="table"}. A significant decrease was observed in the total fat mass as early as at week 4, and this decrease continued until week 24, followed by a stable phase until week 52.

![Changes in the bodyweight, body mass index and abdominal circumference. Mean changes from the baseline (bodyweight 78.6 ± 13.3 kg, BMI 28.0 ± 3.4, abdominal circumference 94.4 ± 9.0 cm) are presented with standard deviations. The change at each time‐point was compared with the baseline value, using the Wilcoxon signed‐rank test, and a significant difference is marked with \*\*\**P* \< 0.001, \*\**P* \< 0.01 or \**P* \< 0.05. The change at week 24 was also compared with that at week 52 using the Wilcoxon signed‐rank test, and an insignificant difference is marked with NS (not significant).](JDI-10-108-g001){#jdi12851-fig-0001}

![Changes in the body components. Mean changes from the baseline (total fat mass 23.5 ± 5.9 kg, lean mass 53.1 ± 10.4 kg, skeletal muscle mass index 7.74 ± 1.23 kg/m^2^, visceral fat area 161.6 ± 52.9 cm^2^, subcutaneous fat area 214.7 ± 84.5 cm^2^) are presented with standard deviations. In the graph of total fat mass + lean mass, the means of the total fat mass are shaded in gray and the means of the lean mass are shaded in light gray. The total fat mass and lean mass data were derived from DXA measurements, visceral fat area and subcutaneous area data were determined from abdominal computed tomography images, and skeletal muscle mass index data were calculated from dual‐energy X‐ray absorptiometry measurements. The change at each time‐point was compared with the baseline value using the Wilcoxon signed‐rank test, and a significant difference is marked with \*\*\**P* \< 0.001, \*\**P* \< 0.01, or \**P* \< 0.05. The change at week 24 was also compared with that at week 52 using the Wilcoxon signed‐rank test and an insignificant difference is marked with NS (not significant).](JDI-10-108-g002){#jdi12851-fig-0002}

###### 

Changes in the body components

                                         Baseline                 Week 24                                                                Week 52
  -------------------------------------- ------------------------ ---------------------------------------------------------------------- ----------------------------------------------------------------------
  Bodyweight (kg)                                                                                                                        
  Observed value                         78.6 (74.1 to 83.0)      76.0 (71.5 to 80.4)                                                    75.5 (71.1 to 79.8)
  Difference from the baseline           --                       −2.63 (−3.51 to −1.75)[\*\*\*](#jdi12851-note-0004){ref-type="fn"}     −3.13 (−4.15 to −2.11)[\*\*\*](#jdi12851-note-0004){ref-type="fn"}
  BMI (kg/m^2^)                                                                                                                          
  Observed value                         28.0 (26.9 to 29.1)      27.1 (25.9 to 28.2)                                                    26.9 (25.8 to 28.0)
  Difference from the baseline           --                       −0.946 (−1.26 to −0.629)[\*\*\*](#jdi12851-note-0004){ref-type="fn"}   −1.11 (−1.46 to −0.753)[\*\*\*](#jdi12851-note-0004){ref-type="fn"}
  Abdominal circumference (cm)                                                                                                           
  Observed value                         94.4 (91.4 to 97.4)      92.4 (89.3 to 95.6)                                                    92.2 (89.0 to 95.3)
  Difference from the baseline           --                       −1.93 (−2.96 to −0.910)[\*\*\*](#jdi12851-note-0004){ref-type="fn"}    −2.21 (−3.27 to −1.15)[\*\*\*](#jdi12851-note-0004){ref-type="fn"}
  Total fat mass (kg)                                                                                                                    
  Observed value                         23.5 (21.5 to 25.5)      21.2 (19.4 to 23.1)                                                    21.2 (19.4 to 23.0)
  Difference from the baseline           --                       −1.97 (−2.66 to −1.28)[\*\*\*](#jdi12851-note-0004){ref-type="fn"}     −1.96 (−2.84 to −1.09)[\*\*\*](#jdi12851-note-0004){ref-type="fn"}
  Lean mass (kg)                                                                                                                         
  Observed value                         53.1 (49.6 to 56.6)      52.1 (48.6 to 55.6)                                                    51.9 (48.3 to 55.5)
  Difference from the baseline           --                       −0.798 (−1.36 to −0.236)[\*\*](#jdi12851-note-0004){ref-type="fn"}     −0.992 (−1.50 to −0.486)[\*\*\*](#jdi12851-note-0004){ref-type="fn"}
  Bone mineral content (g)                                                                                                               
  Observed value                         2,446 (2,274 to 2,617)   2,415 (2,245 to 2,584)                                                 2,419 (2,250 to 2,588)
  Difference from the baseline           --                       −15.3 (−31.9 to 1.28)                                                  −11.4 (−28.5 to 5.73)
  Skeletal muscle mass index (kg/m^2^)                                                                                                   
  Observed value                         7.74 (7.32 to 8.16)      7.59 (7.18 to 8.00)                                                    7.53 (7.10 to 7.96)
  Difference from the baseline           --                       −0.113 (−0.261 to 0.0351)                                              −0.155 (−0.287 to −0.0237)[\*](#jdi12851-note-0004){ref-type="fn"}
  Visceral fat area (cm^2^)                                                                                                              
  Observed value                         162 (144 to 179)         150 (133 to 167)                                                       151 (131 to 170)
  Difference from the baseline           --                       −11.2 (−22.3 to −0.132)                                                −9.59 (−20.6 to 1.38)
  Subcutaneous fat area (cm^2^)                                                                                                          
  Observed value                         215 (187 to 243)         204 (173 to 235)                                                       200 (173 to 228)
  Difference from the baseline           --                       −17.3 (−32.8 to −1.75)[\*\*](#jdi12851-note-0004){ref-type="fn"}       −18.1 (−27.3 to −8.87)[\*\*\*](#jdi12851-note-0004){ref-type="fn"}

Data presented as mean (95% confidence interval): not applicable, *n* for each measurement. Refer to Table [S8](#jdi12851-sup-0009){ref-type="supplementary-material"}. \*\*\**P* \< 0.001, \*\**P* \< 0.01 or \**P* \< 0.05.
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In contrast, it should be noted that there was no significant decrease in the SMI at week 24 of treatment. Furthermore, the BMC data were different from the total fat mass data. As shown in Table [3](#jdi12851-tbl-0003){ref-type="table"} and [Table S6](#jdi12851-sup-0007){ref-type="supplementary-material"}, no significant deviation from the basal BMC value was observed at all the evaluation points up to week 52, except at week 12 (−21.4 g, 95% confidence interval −39.0 to 03.86, *P* = 0.014).

Although the total fat mass decreased, the visceral fat area showed different changes. As shown in Table [3](#jdi12851-tbl-0003){ref-type="table"}, the visceral fat area did not show a significant change during the treatment course.

Changes in the clinical parameters over time {#jdi12851-sec-0016}
--------------------------------------------

The changes in the clinical parameters over time are summarized in Table [2](#jdi12851-tbl-0002){ref-type="table"} and Table [S5](#jdi12851-sup-0006){ref-type="supplementary-material"}. The levels of the serum ketones, including β‐hydroxybutyrate and acetoacetate, significantly increased at week 4 and subsequently, the levels were maintained until week 52. The level of β‐hydroxybutyrate peaked at week 52 (137 ± 338, *P* \< 0.001), but did not reach a dangerously high level at any point.

Factors that changed in association with the changes in the total fat mass and visceral fat area {#jdi12851-sec-0017}
------------------------------------------------------------------------------------------------

The changes in the HbA1c levels did not significantly correlate with the changes in the bodyweight (BW), BMI or body components. The correlations of the changes in the total fat mass and subcutaneous fat area with the clinical parameters are summarized in Table [4](#jdi12851-tbl-0004){ref-type="table"}a and Table [4](#jdi12851-tbl-0004){ref-type="table"}b, respectively. The change in the total fat mass showed a strong positive correlation with the change in the subcutaneous fat area at week 24 (*r* = 0.491, *P* = 0.004), as well as at week 52 (*r* = 0.540, *P* \< 0.001). The change in the total fat mass also showed a significant positive correlation with the changes in the levels of serum ketones and free fatty acids at week 24. The visceral fat area was positively correlated with the changes in the BW and BMI, but not significantly correlated with the changes in the parameters characteristic of metabolic syndrome; that is, abdominal circumference, and levels of fasting plasma glucose, triglyceride and high‐density lipoprotein cholesterol. Furthermore, no correlation was detected for the changes in the serum ketone levels or free fatty acid levels, which reflect fat degradation.

###### 

Correlation of the change in the (a) total fat mass during treatment with the clinical parameters, (b) Correlation of the change in the visceral fat area during treatment with the clinical parameters

                                        Correlation with the change in the total fat mass (Spearman\'s rank‐order correlation analysis)                                                                                                                                                     
  ------------------------------------- ------------------------------------------------------------------------------------------------- ----------- ------------------------------------------------------ ------- ----------- ---------------------------------------------------------- -------
  \(a\)                                                                                                                                                                                                                                                                                     
  Bodyweight (kg)                       36                                                                                                0.287       0.089                                                  36      **0.442**   **0.006** [\*\*](#jdi12851-note-0005){ref-type="fn"}       
  Abdominal circumference (cm)          36                                                                                                **0.393**   **0.017** [\*](#jdi12851-note-0005){ref-type="fn"}     36      **0.549**   **\<0.001** [\*\*\*](#jdi12851-note-0005){ref-type="fn"}   
  BMI (kg/m^2^)                         36                                                                                                **0.334**   **0.045** [\*](#jdi12851-note-0005){ref-type="fn"}     36      **0.423**   **0.009** [\*\*](#jdi12851-note-0005){ref-type="fn"}       
  Glucose metabolism                    FPG (mmol/L)                                                                                      36          −0.0287                                                0.868   36          0.264                                                      0.120
  HbA1c (%)                             36                                                                                                0.0459      0.791                                                  36      0.0966      0.577                                                      
  F‐IRI (pmol/L)                        36                                                                                                −0.0646     0.710                                                  36      0.130       0.453                                                      
  F‐CPR (nmol/L)                        36                                                                                                0.133       0.440                                                  36      0.268       0.114                                                      
  Body component                        Lean mass (kg)                                                                                    36          −0.153                                                 0.374   36          −0.0891                                                    0.608
  SMI (kg/m^2^)                         36                                                                                                −0.252      0.139                                                  36      0.0831      0.632                                                      
  Visceral fat area (cm^2^)             31                                                                                                0.121       0.520                                                  34      0.218       0.217                                                      
  Subcutaneous fat area (cm^2^)         31                                                                                                **0.491**   **0.004** [\*\*](#jdi12851-note-0005){ref-type="fn"}   34      **0.540**   **\<0.001** [\*\*\*](#jdi12851-note-0005){ref-type="fn"}   
  HDL‐C (mmol/L)                        36                                                                                                −0.200      0.245                                                  36      −0.149      0.388                                                      
  TG (mmol/L)                           36                                                                                                −0.209      0.223                                                  36      0.00103     0.995                                                      
  FFA (μmol/L)                          36                                                                                                **0.363**   **0.028** [\*](#jdi12851-note-0005){ref-type="fn"}     36      0.222       0.195                                                      
  Acetoacetate (μmol/L)                 36                                                                                                **0.360**   **0.030** [\*](#jdi12851-note-0005){ref-type="fn"}     36      0.0897      0.605                                                      
  β‐hydroxybutyrate (μmol/L)            36                                                                                                **0.348**   **0.036** [\*](#jdi12851-note-0005){ref-type="fn"}     36      0.100       0.563                                                      
  Urine glucose excretion (mmol/24 h)   19                                                                                                −0.0842     0.735                                                  19      0.140       0.572                                                      

                                        Correlation with the change in the visceral fat area (Spearman\'s rank‐order correlation analysis)                                                                                                                                             
  ------------------------------------- ---------------------------------------------------------------------------------------------------- ----------- ---------------------------------------------------- ------- ----------- ---------------------------------------------------- -------
  \(b\)                                                                                                                                                                                                                                                                                
  Bodyweight (kg)                       32                                                                                                   **0.400**   **0.022** [\*](#jdi12851-note-0005){ref-type="fn"}   35      **0.390**   **0.020** [\*](#jdi12851-note-0005){ref-type="fn"}   
  Abdominal circumference (cm)          32                                                                                                   0.190       0.299                                                35      0.259       0.133                                                
  BMI (kg/m^2^)                         32                                                                                                   **0.420**   **0.016** [\*](#jdi12851-note-0005){ref-type="fn"}   35      **0.389**   **0.020** [\*](#jdi12851-note-0005){ref-type="fn"}   
  Glucose metabolism                    FPG (mmol/L)                                                                                         32          0.283                                                0.117   35          0.103                                                0.557
  HbA1c (%)                             32                                                                                                   0.330       0.064                                                35      0.0997      0.571                                                
  F‐IRI (pmol/L)                        32                                                                                                   0.0942      0.610                                                35      0.136       0.440                                                
  F‐CPR (nmol/L)                        32                                                                                                   0.215       0.240                                                35      0.170       0.331                                                
  Body component                        Total fat mass (kg)                                                                                  31          0.121                                                0.520   34          0.218                                                0.217
  Lean mass (kg)                        31                                                                                                   0.224       0.228                                                34      0.149       0.404                                                
  Fat/lean ratio                        31                                                                                                   0.0597      0.751                                                34      0.126       0.479                                                
  SMI (kg/m^2^)                         31                                                                                                   0.0968      0.607                                                34      0.00504     0.977                                                
  Subcutaneous fat area (cm^2^)         32                                                                                                   0.150       0.417                                                35      −0.0815     0.644                                                
  HDL‐C (mmol/L)                        32                                                                                                   −0.144      0.435                                                35      −0.182      0.296                                                
  TG (mmol/L)                           32                                                                                                   0.223       0.222                                                35      0.0342      0.846                                                
  FFA (μmol/L)                          32                                                                                                   0.311       0.083                                                35      0.330       0.052                                                
  Acetoacetate (μmol/L)                 32                                                                                                   0.209       0.254                                                35      −0.0111     0.950                                                
  β‐hydroxybutyrate (μmol/L)            32                                                                                                   0.196       0.285                                                35      −0.0210     0.905                                                
  Urine glucose excretion (mmol/24 h)   20                                                                                                   −0.144      0.548                                                20      −0.211      0.378                                                

The correlation of the change from the baseline in the (a) total fat mass (dual‐energy X‐ray absorptiometry) or (b) visceral fat area (determined from computed tomography image) at each time‐point with the changes in each clinical parameter was evaluated using Spearman\'s rank‐order correlation. \*\*\**P* \< 0.001, \*\**P* \< 0.01 or \**P* \< 0.05. Significant difference at *P* \< 0.05. Data with significant difference are shown in bold. F‐CPR, fasting plasma C‐peptide immunoreactivity; FFA, free fatty acid; F‐IRI, fasting plasma insulin; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL‐C, high‐density lipoprotein cholesterol; SMI, skeletal muscle mass index; TG, triglyceride.
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Relationship between the baseline values of the parameters and the changes in the total fat mass and visceral fat area {#jdi12851-sec-0018}
----------------------------------------------------------------------------------------------------------------------

An analysis was carried out to investigate the correlation of the changes in the total fat mass with the baseline factors, after luseogliflozin treatment (Table [5](#jdi12851-tbl-0005){ref-type="table"}a). A decrease in the total fat mass at week 52 was significantly negatively correlated with the total fat mass at the baseline (*r* = −0.350, *P* = 0.035). In addition, the decrease in the total fat mass at week 52 showed a significant negative correlation with the extent of urine glucose excretion at the baseline (*r* = −0.440, *P* = 0.045).

###### 

Correlation of the change in the (a) total fat mass during treatment with the clinical parameters at the baseline, (b) visceral fat area during treatment with the clinical parameters at the baseline

  Baseline value                        Correlation with the change in the total fat mass (Spearman\'s rank‐order correlation analysis)                                                                                                                                               
  ------------------------------------- ------------------------------------------------------------------------------------------------- ------------ ---------------------------------------------------- ------- ------------ ---------------------------------------------------- ----------------------------------------------------
  \(a\)                                                                                                                                                                                                                                                                               
  Bodyweight (kg)                       36                                                                                                0.0555       0.750                                                36      −0.0915      0.598                                                
  Abdominal circumference (cm)          36                                                                                                0.0417       0.810                                                36      −0.131       0.449                                                
  BMI (kg/m^2^)                         36                                                                                                −0.113       0.514                                                36      −0.153       0.376                                                
  Glucose metabolism                    FPG (mmol/L)                                                                                      36           −0.000644                                            0.997   36           −0.116                                               0.504
  HbA1c (%)                             36                                                                                                −0.235       0.169                                                36      −0.217       0.204                                                
  F‐IRI (pmol/L)                        36                                                                                                −0.143       0.408                                                36      −0.0435      0.802                                                
  F‐CPR (nmol/L)                        36                                                                                                −0.241       0.158                                                36      −0.101       0.562                                                
  Body component                        Total fat mass (kg)                                                                               36           −0.325                                               0.053   36           −**0.350**                                           **0.035** [\*](#jdi12851-note-0006){ref-type="fn"}
  Lean mass (kg)                        36                                                                                                0.156        0.366                                                36      0.00180      0.991                                                
  Fat/lean ratio                        36                                                                                                −**0.369**   **0.025** [\*](#jdi12851-note-0006){ref-type="fn"}   36      −0.315       0.061                                                
  SMI (kg/m^2^)                         36                                                                                                0.131        0.450                                                36      −0.0716      0.680                                                
  Visceral fat area (cm^2^)             36                                                                                                0.170        0.323                                                36      0.238        0.162                                                
  Subcutaneous fat area (cm^2^)         36                                                                                                −0.178       0.300                                                36      −**0.351**   **0.035** [\*](#jdi12851-note-0006){ref-type="fn"}   
  HDL‐C (mmol/L)                        36                                                                                                0.220        0.198                                                36      0.254        0.136                                                
  TG (mmol/L)                           36                                                                                                0.287        0.090                                                36      0.0395       0.820                                                
  FFA (μmol/L)                          36                                                                                                0.0667       0.701                                                36      0.0189       0.913                                                
  Acetoacetate (μmol/L)                 36                                                                                                0.0463       0.789                                                36      0.0117       0.946                                                
  β‐hydroxybutyrate (μmol/L)            36                                                                                                −0.0669      0.700                                                36      −0.0422      0.808                                                
  Urine glucose excretion (mmol/24 h)   21                                                                                                −0.174       0.455                                                21      −**0.440**   **0.045** [\*](#jdi12851-note-0006){ref-type="fn"}   

  Baseline value                        Correlation with the change in the visceral fat area (Spearman\'s rank‐order correlation analysis)                                                                                                                                                       
  ------------------------------------- ---------------------------------------------------------------------------------------------------- ------------ ------------------------------------------------------ ------- ------------ ---------------------------------------------------------- -------
  \(b\)                                                                                                                                                                                                                                                                                          
  Bodyweight (kg)                       32                                                                                                   0.0764       0.680                                                  35      0.140        0.425                                                      
  Abdominal circumference (cm)          32                                                                                                   −0.00294     0.987                                                  35      0.177        0.312                                                      
  BMI (kg/m^2^)                         32                                                                                                   0.0367       0.843                                                  35      0.0961       0.585                                                      
  Glucose metabolism                    FPG (mmol/L)                                                                                         32           −0.00220                                               0.990   35           0.107                                                      0.545
  HbA1c (%)                             32                                                                                                   0.203        0.267                                                  35      0.164        0.350                                                      
  F‐IRI (pmol/L)                        32                                                                                                   −0.0663      0.720                                                  35      0.113        0.520                                                      
  F‐CPR (nmol/L)                        32                                                                                                   −0.0729      0.694                                                  35      0.0602       0.732                                                      
  Body component                        Total fat mass (kg)                                                                                  31           0.0141                                                 0.940   34           0.209                                                      0.237
  Lean mass (kg)                        31                                                                                                   0.0625       0.740                                                  34      0.0576       0.748                                                      
  Fat/lean ratio                        31                                                                                                   −0.0238      0.899                                                  34      0.0735       0.681                                                      
  SMI (kg/m^2^)                         31                                                                                                   0.0194       0.918                                                  34      0.00474      0.979                                                      
  Visceral fat area (cm^2^)             32                                                                                                   −**0.399**   **0.023**\*                                            35      −0.183       0.296                                                      
  Subcutaneous fat area (cm^2^)         32                                                                                                   0.110        0.550                                                  35      0.318        0.062                                                      
  HDL‐C (mmol/L)                        32                                                                                                   0.0228       0.902                                                  35      0.232        0.182                                                      
  TG (mmol/L)                           32                                                                                                   −0.0381      0.837                                                  35      −0.0228      0.897                                                      
  FFA (μmol/L)                          32                                                                                                   −**0.353**   **0.047** [\*](#jdi12851-note-0006){ref-type="fn"}     35      −**0.498**   **0.002** [\*\*](#jdi12851-note-0006){ref-type="fn"}       
  Acetoacetate (μmol/L)                 32                                                                                                   −0.226       0.216                                                  35      −0.265       0.124                                                      
  β‐Hydroxybutyrate (μmol/L)            32                                                                                                   −**0.458**   **0.007** [\*\*](#jdi12851-note-0006){ref-type="fn"}   35      −**0.549**   **\<0.001** [\*\*\*](#jdi12851-note-0006){ref-type="fn"}   
  Urine glucose excretion (mmol/24 h)   20                                                                                                   −0.281       0.233                                                  20      −0.292       0.215                                                      

To investigate the baseline clinical parameters that correlate with the change in the total fat mass or visceral fat area, the change from the baseline in the (a) total fat mass or (b) visceral fat area at week 24 and week 52 was evaluated for the correlation with the baseline value of each clinical parameter, using Spearman\'s rank‐order correlation. \*\*\**P* \< 0.001, \*\**P* \< 0.01 or \**P* \< 0.05. Significant difference at *P* \< 0.05. Data with significant difference are shown in bold. BMI, body mass index; F‐CPR, fasting plasma C‐peptide immunoreactivity; F‐CPR, fasting plasma C‐peptide immunoreactivity; FFA, free fatty acid; F‐IRI, fasting plasma insulin; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL‐C, high‐density lipoprotein cholesterol; SMI, skeletal muscle mass index; TG, triglyceride.
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Analyses were also carried out to investigate the correlation of the changes in the visceral fat area with various baseline factors. As shown in Table [5](#jdi12851-tbl-0005){ref-type="table"}b and Figure [3](#jdi12851-fig-0003){ref-type="fig"}, the changes in the visceral fat area at week 24, on an individual basis, showed a significant negative correlation with the extent of the visceral fat area at the baseline (*r* = −0.399, *P* = 0.023). In particular, the visceral fat area at week 24 was decreased in all the patients in whom the baseline visceral fat area was ≥187 cm^2^.

![Correlation of the individual changes in the visceral fat area with the visceral fat area at the baseline. The changes in the visceral fat area at week 24 in individual patients showed a significant negative correlation with the respective visceral fat area levels at the baseline (*r* = −0.457, *P* = 0.0085). In particular, the visceral fat area at week 24 was decreased in all the patients in whom the baseline visceral fat area was ≥187 cm^2^.](JDI-10-108-g003){#jdi12851-fig-0003}

The changes in the total fat mass and visceral fat area, both at weeks 24 and 52, did not show a significant correlation with the HbA1c levels, abdominal circumference or BMI.

Adverse events {#jdi12851-sec-0019}
--------------

The adverse events and adverse drug reactions observed in the present study are summarized in Table [S7](#jdi12851-sup-0008){ref-type="supplementary-material"}. During the study period, two patients were hospitalized due to serious adverse events, for which a causal relationship with the study drug was ruled out. Nine events of adverse drug reactions, possibly related to luseogliflozin use, were reported in eight patients (20.5%). All the adverse drug reactions were previously known and mild in severity. The serum ketones did not reach a dangerously high level.

Discussion {#jdi12851-sec-0020}
==========

In the present study, a decrease in the total fat mass was detected early in the treatment, at week 4. The time‐course profile showed a rapid decrease in the first half of the treatment period, until week 24. In the first half, a decrease in the total fat mass was significantly correlated with an increase in the level of ketones, which are generated as a result of fat degradation. This suggests that a marked metabolic change occurred within the adipose tissues in the first half of the treatment, until week 24. A previous study with other SGLT2 inhibitors also reported decreases in the total fat mass and lean mass[1](#jdi12851-bib-0001){ref-type="ref"}. The present study determined the body composition using DXA, which involves less interference from body fluids than the bioimpedance method. In addition, the DXA method is capable of measuring the lean mass, focusing only on the limbs. Therefore, the SMI -- which is based on the lean mass of the extremities -- as measured using DXA, is a suitable indicator for the estimation of true skeletal muscle mass. The present study showed that the SMI decreased over the course of the treatment, but the degree of the change was small. To maintain adequate levels of skeletal muscle mass during type 2 diabetes treatment with SGLT2‐i, further investigations are required, which focus on the type of diet therapy that is suitable in the early stages of treatment up to week 36, during which period drastic changes in the metabolism are followed by changes in the SMI.

Visceral fat accumulation is considered to have adverse metabolic and atherogenic effects. In the present study, the visceral fat area tended to decrease through the course of the treatment, though the change was not significant, and also showed a significant correlation with the change in the BW at weeks 24 and 52, and in the BMI. The present study was carried out to investigate the effect of SGLT2‐i on the body composition of Japanese type 2 diabetes patients with a BMI between 20 and 35 kg/m^2^, who were not deemed severely overweight. To date, studies carried out in the USA and European Union that investigated the changes in the body composition caused by SGLT2‐i treatment focused predominantly on severely overweight patients with a BMI of 35 kg/m^2^ or higher[9](#jdi12851-bib-0009){ref-type="ref"}. However, the present study evaluated patients with relatively lower body fat levels at the baseline, and did not detect a significant change in the visceral fat area during the course of treatment. This might be attributed to potential differences in the drug effectiveness as a result of the lower body fat levels at the baseline, when the study participants started taking SGLT2‐i. In fact, the present study showed a significant negative correlation between the baseline visceral fat level and its change during treatment, as shown in Figure [3](#jdi12851-fig-0003){ref-type="fig"}; the higher the baseline visceral fat level, the greater the decrease in the visceral fat. This is an important finding, in that it indicates the type of Japanese type 2 diabetes patients in whom this drug\'s use might be preferable.

Furthermore, we found that the change in the visceral fat area did not have a significant correlation with the change in the levels of triglyceride, high‐density lipoprotein cholesterol or HbA1c. This could be attributed to the mechanism that the lowering of blood glucose levels through the use of SGLT2‐i is mainly mediated by an increase in urinary glucose levels, but not directly associated with body fat mass reduction. As the mechanism of body fat mass reduction also involves an increase in the level of urinary glucose, which stimulates an increase in glyconeogenesis and the ultimate enhancement of lipolysis, the changes in the blood glucose and HbA1c levels do not necessarily correlate with the reduction of body fat.

In the present study, we confirmed that the total fat mass significantly decreased through the effect of luseogliflozin, which promotes fat degradation in the adipose tissues. However, we were unable to elaborate on the mechanism underlying the greater reduction in subcutaneous fat than visceral fat. However, because the decrease in the total fat mass was significantly correlated with the decrease in the abdominal circumference, monitoring the abdominal circumference in routine clinical practice is recommended for the estimation of fat mass changes. The present findings show that, unlike the visceral fat area at the baseline, BW, BMI, abdominal circumference and HbA1c levels at the baseline are not predictors of body fat reduction.

The present study had some limitations. First, because of its single‐arm design, without a control group, this study was unable to compare the changes in the body composition that might be observed without SGLT2‐i treatment. Additionally, the present study did not collect information on the compliance with diet therapy and exercise therapy. Due to a lack of information, we could not clarify why no correlation was observed between the changes in the visceral fat and HbA1c levels. Another concern is the potential effect of sex on metabolism; however, owing to the limited sample size, we were unable to carry out analyses by sex.

Except for glucose metabolism, significant changes were observed in the atherogenic factors, and triglyceride and high‐density lipoprotein cholesterol levels, and a lowering of blood pressure was also observed. Although increases in low‐density lipoprotein cholesterol levels were reported during the course of treatment with other SGLT2‐i drugs,[11](#jdi12851-bib-0011){ref-type="ref"} the present study did not detect a significant change in the low‐density lipoprotein cholesterol levels during the course of treatment. Furthermore, our study showed a significant increase in the blood adiponectin levels, which was a favorable outcome. It is of significance that, in Japanese type 2 diabetes patients with a moderate BMI, we observed a significant increase in the adiponectin level through SGLT2‐i treatment, along with the observation of the time‐course profile of the body composition. A significant decrease in urine albumin excretion was also observed, supporting a favorable effect on the kidney.[12](#jdi12851-bib-0012){ref-type="ref"}

In the present study, no new symptoms or serious symptoms were reported as adverse drug reactions, indicating favorable tolerability. In conclusion, combination therapy, involving the use of luseogliflozin and other oral hypoglycemic agents, in the treatment of Japanese type 2 diabetes patients is expected to provide better long‐term glycemic control and improvements in the body composition and atherogenic factors, even in actual clinical practice.
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